http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cytosorbents (CTSO) Secures Up to $3M Award in SBIR Phase IIB Funding by NIH/NHLBI to Accelerate U.S. Approval & Commercialization of HemoDefend Blood Transfusion Filter
-
CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
-
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
-
CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide
-
CytoSorbents to Report Q2 2018 Operating and Financial Results
-
Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society
-
CytoSorbents Added to the Russell 2000 and Russell 3000 Indexes
-
CytoSorbents Officially Opens New U.S. CytoSorb Manufacturing Facility
-
CytoSorbents to Present at the Jefferies 2018 Global Healthcare Conference
-
CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference
-
Cytosorbents (CTSO) Reports Addition of Bilirubin and Myoglobin Reduction to EU Approved Indications for Use
-
CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
-
CytoSorbents Reports Strong First Quarter 2018 Financial Results
-
CytoSorbents to Report Q1 2018 Operating and Financial Results
-
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
-
CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich
-
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
-
CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference
-
CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference
-
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
-
CytoSorbents to Report Fiscal 2017 Operating and Financial Results
-
CytoSorbents to Participate at the BTIG Healthcare Conference
-
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
-
CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
-
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
-
Cytosorbents (CTSO) Pre-Announces Prelim. 4Q & FY17 Revenues Slightly Above Consensus; CEO Dr. Phillip Chan Release Shareholder Letter
-
CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter
-
CytoSorbents To Provide Corporate Update at Biotech Showcase 2018
-
Cytosorbents (CTSO) Announces FDA Approval of U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application with Conditions
-
CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application
-
CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
-
German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial
-
CytoSorbents to Present at the LD Micro Main Event Investor Conference
-
CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017
-
CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America
-
CytoSorbents to Report Q3 2017 Operating and Financial Results
-
CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia
-
CytoSorb® Usage During Valve Replacement Surgery for Infective Endocarditis Helps Stabilize Patients and May Improve Survival
-
CytoSorbents to Present at the 2017 BIO Investor Forum
-
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
-
Cytosorbents (CTSO) Says Key Clinical Study Shows Reversal of Refractory Septic Shock in Patients Treated with CytoSorb
-
Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
-
World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony
-
Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation
-
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
-
CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium
-
Cytosorbents (CTSO) Secures $719K Grant to Acutely Stabilize Severe Burn Patients
-
CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients
-
CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017
-
CytoSorbents to Report Q2 2017 Operating and Financial Results

